Allopurinol Hypersensitivity — HLA-B*58:01, the allele that turns the world's most prescribed gout medication into a life-threatening Stevens-Johnson reaction, present in up to 8% of Han Chinese patients.
Whole genome sequencing provides complete HLA class I typing — covering HLA-B*58:01 and all other pharmacogenomically actionable HLA alleles simultaneously — enabling allopurinol safety assessment before the first dose.
Allopurinol Hypersensitivity — HLA-B*58:01
Allopurinol is the most commonly prescribed urate-lowering therapy for gout and hyperuricemia, used by tens of millions of patients worldwide. In a subset of patients, allopurinol triggers severe cutaneous adverse reactions — allopurinol hypersensitivity syndrome (AHS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). The mortality rate of allopurinol-induced TEN is approximately 20-30%, and allopurinol-induced SJS accounts for a disproportionate share of all SJS cases in Southeast Asian populations, where gout is common and HLA-B*58:01 is prevalent.
HLA-B*58:01 is the primary genetic risk factor for allopurinol-induced severe cutaneous adverse reactions. The allele frequency of HLA-B*58:01 varies substantially by ethnicity: approximately 6-8% in Han Chinese, 6-8% in Thai, 3-4% in Korean, 2% in Vietnamese, less than 1% in European and African ancestry populations. In Han Chinese populations, essentially all cases of allopurinol-induced SJS/TEN occur in HLA-B*58:01 carriers — the positive predictive value is high enough that prospective HLA-B*58:01 screening programs in Taiwan have dramatically reduced allopurinol-induced SJS/TEN in that population. The mechanism involves HLA-B*58:01-mediated antigen presentation of allopurinol or its metabolites to CD8+ cytotoxic T cells.
CPIC Level A guidelines for allopurinol and HLA-B*58:01 recommend that HLA-B*58:01-positive patients be prescribed an alternative urate-lowering agent (febuxostat, probenecid, or pegloticase). For HLA-B*58:01-negative patients, allopurinol is safe to prescribe from an HLA pharmacogenomics standpoint. These guidelines have been formally adopted by regulatory agencies in Taiwan (mandatory screening before allopurinol), Thailand, and Hong Kong, with increasing adoption elsewhere as pharmacogenomics-guided prescribing infrastructure expands. In the United States, CPIC recommends testing in all patients of Asian ancestry before allopurinol initiation.
HLA-B*58:01 single-allele commercial tests exist for Asian populations. Whole genome sequencing adds comprehensive HLA typing — covering all pharmacogenomic HLA risk alleles (B*58:01, B*15:02, B*57:01, A*31:01) simultaneously for complete prescribing safety across multiple drug classes.
A single HLA-B*58:01 result answers only the allopurinol question — complete HLA typing answers many more
Point-of-care HLA-B*58:01 tests are designed to answer a single pharmacogenomic question before a single drug. A patient with gout who is also on HIV therapy, epilepsy medication, or who will need chemotherapy in the future has multiple pharmacogenomic HLA questions simultaneously: HLA-B*58:01 (allopurinol), HLA-B*57:01 (abacavir), HLA-B*15:02 (carbamazepine), and HLA-A*31:01 (carbamazepine in non-Asian populations). Complete HLA typing from whole genome sequencing answers all of these questions in a single test, providing a lifetime pharmacogenomic record that covers all known and future HLA-drug associations.
Febuxostat — the alternative to allopurinol — has its own considerations that require clinical context
HLA-B*58:01 carriers who cannot take allopurinol are typically offered febuxostat (Uloric) as an alternative XO inhibitor for uric acid lowering. Febuxostat does not have HLA associations and does not cause SJS/TEN. However, febuxostat carries a warning of cardiovascular events in patients with established cardiovascular disease (based on the CARES trial), making it a less suitable alternative for some patients with cardiovascular comorbidities and gout. Providing complete HLA typing — establishing that a patient is HLA-B*58:01 positive before allopurinol is ever prescribed — allows the clinician to select febuxostat or another urate-lowering strategy from the outset, in the context of a comprehensive clinical assessment.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Allopurinol Hypersensitivity — HLA-B*58:01 and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
